AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate wins two new indications based on pivotal DESTINY-Breast11 and DESTINY-Breast05 trials, reshaping …
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate wins two new indications based on pivotal DESTINY-Breast11 and DESTINY-Breast05 trials, reshaping …
The FDA approval of Xocova marks a new front in the antiviral arsenal, shifting from treatment to prevention …
BioMarin Pharmaceutical has announced positive pivotal Phase 3 results for VOXZOGO (vosoritide) in children with hypochondroplasia, the most …
A phase 1 pilot trial suggests that a novel egg-shell derived peptide may reduce Alzheimer’s biomarkers and improve …
One company faces regulatory setback while another achieves a Phase III victory, highlighting both urgency and uncertainty in …
First 16-week data from the APEX Part A trial reveal APG777 could raise the bar for biologics in …
SUMMIT trial shows bezuclastinib reduces symptom burden and mast cell markers significantly in non-advanced systemic mastocytosis
In the VERIFY study rusfertide demonstrated both safety and efficacy in reducing phlebotomy dependence for patients with polycythemia …
Company Overview and Focus Biodexa Pharmaceuticals PLC, a clinical-stage biotechnology company dedicated to developing innovative treatments for diseases …
Continued program expansion strengthens potential to deliver an all-oral, pan-genotypic next-generation HCV therapy.
Already a subscriber? Log in